Anixa Biosciences announces Notice of Allowance of additional patent

Anixa Biosciences announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance broadening protection of Anixa’s novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic. The patent is titled “Ovarian Cancer Vaccines,” and covers nucleic acid-based delivery of the vaccine. The lead inventor is the late Dr. Vincent Tuohy of Cleveland Clinic. This ovarian cancer vaccine targets the extracellular domain of anti-Mullerian hormone receptor 2, which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.